(Z)-LFM-A13
Product Sizes
50 mg
HY-18009-50MG
10 mg
HY-18009-10MG
5 mg
HY-18009-5MG
10mM/1mL
HY-18009-10MM
25 mg
HY-18009-25MG
100 mg
HY-18009-100MG
200 mg
HY-18009-200MG
About this Product
- SKU:
- HY-18009
- CAS Number:
- 244240-24-2
- Extra Details:
- LFM-A13 is a potent BTK; JAK2; PLK inhibitor; inhibits recombinant BTK; Plx1 and PLK3 with IC50s of 2.5 μM; 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3; Src family kinase HCK; EGFR and IRK.
- Molecular Weight:
- 360.01
- Purity:
- 99.80
- References:
- [1]Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99.|[2]van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13.|[3]"Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2017 Nov 15. "|[4]Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
